Duloxetine (Cymbalta) for Anxiety
Yes, duloxetine is FDA-approved and effective for generalized anxiety disorder (GAD) in adults, with a recommended starting dose of 60 mg once daily (or 30 mg once daily for one week if tolerability is a concern), and a target dose of 60 mg once daily for maintenance treatment.
FDA-Approved Indication
Duloxetine is specifically indicated for the treatment of generalized anxiety disorder in adults 1. The FDA approval is based on multiple short-term efficacy trials and maintenance studies demonstrating superiority over placebo.
Dosing Strategy
Initial Treatment
- Standard approach: Start at 60 mg once daily 1
- For tolerability concerns: Start at 30 mg once daily for 1 week, then increase to 60 mg once daily 1
- Can be taken without regard to meals or time of day 1
- Swallow whole; do not crush, chew, or open capsules 1
Target Dose
- 60 mg once daily is the optimal dose for most patients 1
- While 120 mg once daily has shown efficacy, there is no evidence that doses above 60 mg/day provide additional benefit 1
- If increasing beyond 60 mg, use 30 mg increments 1
- Maximum studied dose: 120 mg once daily (safety above this not established) 1
Evidence of Efficacy
Duloxetine demonstrated superiority over placebo across multiple measures in GAD:
- Anxiety symptoms: Significant improvement on Hamilton Anxiety Scale (HAM-A) total scores in three short-term trials 1, 2, 3
- Functional impairment: Greater improvement on Sheehan Disability Scale across work, social, and family domains 2, 4
- Response rates: Higher proportion achieving ≥50% reduction in HAM-A scores 2
- Relapse prevention: Significantly longer time to relapse compared to placebo in maintenance studies 1
The evidence shows duloxetine performs comparably to venlafaxine XR (another SNRI) in head-to-head comparison 3, supporting its position as a first-line treatment option 5, 6.
Clinical Considerations
Tolerability Profile
Common adverse events include 5, 2:
- Nausea (most common, often transient)
- Dizziness
- Dry mouth
- Somnolence
- Constipation
- Fatigue
Key point: Most adverse events are mild to moderate in severity. Discontinuation rates due to adverse events are higher than placebo (approximately 11-14% vs 2%) 3, with nausea being the primary reason 5.
Special Populations
- Elderly (≥65 years): Duloxetine is effective in older adults with GAD 5
- Renal impairment: Use lower starting dose and gradual titration 1
- Hepatic impairment: Avoid in patients with substantial hepatic dysfunction
Duration of Treatment
- Acute treatment: 9-10 weeks to establish response 1
- Maintenance: GAD typically requires several months or longer of sustained pharmacological therapy 1
- Continue at 60-120 mg once daily for maintenance in responders 1
Additional Benefits
For GAD patients presenting with comorbid pain symptoms (common in anxiety disorders), duloxetine offers dual benefit by reducing both anxiety and pain severity 4. This makes it particularly advantageous when physical symptoms accompany anxiety.
Discontinuation
When stopping duloxetine, taper gradually rather than abrupt cessation. Discontinuation-emergent adverse events (primarily nausea and dizziness) occur in up to one-third of patients 5, though these are generally less problematic than with some other SNRIs like venlafaxine 3.
Drug Interactions
- Avoid: Potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin)
- Use caution: Drugs metabolized by CYP2D6, particularly those with narrow therapeutic index
- Duloxetine is a moderate CYP2D6 inhibitor 5
Bottom Line Algorithm
- Start: 60 mg once daily (or 30 mg daily × 1 week if concerned about tolerability)
- Target: 60 mg once daily for maintenance
- If inadequate response at 60 mg: May increase to 90-120 mg once daily, though additional benefit is uncertain
- Monitor: Response at 9-10 weeks; continue for several months if effective
- Discontinue: Taper gradually to minimize withdrawal symptoms